Waterhouse, DM, Rothschild, S, Dooms, C, Mennecier, B, Bozorgmehr, F, Majem, M, Heuvel, MHV, Linardou, H, Cho, BC, Roberts-Thomson, R, Tanaka, K, Blais, N, Schvartsman, G, Hansen, KH, Chmielewska, I, Forster, MD, Giannopoulou, C, Stollenwerk, B, Obiozor, CC, Wang, Y, Novello, S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. LUNG CANCER. 2024; 196DOI:10.1016/j.lungcan.2024.107921. PMID:39303400. IF:4.400(Q1/2D).

de Castro, J, Dols, MC, Gómez, MD, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Campelo, RG. Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Jones, DR, Wakelee, H, Spicer, JD, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Wang, W, Chen, H, Dooms, C, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Huang, HC, Novello, S, Jensen, E, Keller, SM, Samkari, A, Kalhor, N. Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, Sullivan, IG, Torrego, A, Surrallés, J, Purdy, J, Carmona, MA, Dunsford, H, Wubs, M. An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).